

Syneron Investor Fact Sheet

June 2010
NASDAQ: ELOS
www.syneron.com

Market Data (as of 6/21/10)

Ticker (NASDAQ)	ELOS
Stock Price	\$10.19
52-Week Range	\$6.50-\$12.44
Average Volume (3mo)	111,705
Shares Outstanding	34.02 M
Market Cap	\$347 M

Analyst Coverage

Gleacher & Co.	Amit Hazan
Maxim	Anthony Vendetti
Needham & Co.	Dalton Chandler

Financial Highlights

1Q 2010 Results:	
Revenue	\$43.0 M
Gross Margin ¹	47.4%
Net (Loss) Income ¹	\$6.2 M
EPS (Fully Diluted) ¹	\$(0.18)
Cash Position ²	\$229.5 M

Overview

Syneron Medical Ltd. is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. In January 2010 Syneron merged with Candela Corporation, creating the largest aesthetic medical device company. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Investment Highlights

The global leader in aesthetic devices (~ 30% WW market share)

- Driving share through global distribution platform, broad and deep product portfolio, and significant cross selling

Most comprehensive product portfolio addressing largest and fastest growing aesthetic device markets

- Complementary solutions in hair removal, skin rejuvenation, lesion/tattoo removal and cellulite reduction
- Expanding recurring revenue streams through service and consumables


Balanced mix of physician customers

Largest worldwide sales / distribution and service network

- Sales in 86 countries
- >60% revenue from international markets (1Q 2010)
- Direct sales in North America and 11 OUS countries

World Class Sales and Distribution

Syneron has an extensive global independent distribution network in all major markets and countries



- ★ Syneron Corporate HQ
- ★ Syneron North America HQ (Irvine, CA)
- Candela Subsidiary HQ (Wayland, MA)
- ◆ Syneron Regional HQ (Toronto Canada / Hong Kong)
- Candela Subsidiary Locations (Australia, France, Germany, Italy, Japan, Portugal, Spain, UK)




1 - Non-GAAP results - excludes stock-based compensation, amortization and one-time expenses
2 - Includes short-term and long-term bank deposits and investments



Syneron Investor Fact Sheet

June 2010
NASDAQ: ELOS
www.syneron.com



Strategic Growth Drivers

6 major product platform launches in growth segments (last 18 months)

- Body shaping product line extensions
- Sublative Rejuvenation™
- Fractional ablative resurfacing
- Multi-color tattoo removal
- Hair removal line extensions

Robust R&D program creating new markets / applications

- Home use (Proctor & Gamble strategic partnership)
- Other aesthetic initiatives – Skin Whitening
- Dental – Teeth Whitening
- 3 new product launches scheduled for 2010

Cross-selling opportunities

- Syneron products through Candela “core” market distribution
- Candela products through Syneron “non-core” market distribution
- Candela and Syneron brands maintained
- Several hundred North American opportunities identified in 1Q 2010

Syneron and Candela - Best-In-Class Product Portfolio

Body Treatments:

- Body Contouring
- Cellulite Reduction
- Laser-Assisted Lipolysis
- Hair Removal
- Leg Veins / Vascular
- Tattoo / Pigment Removal

Facial Treatments:

- Fractional Skin Treatment (Ablative & Non-Ablative)
- Wrinkle Reduction
- Skin Rejuvenation
- Skin Tightening
- Acne Treatment

Management

Shimon Eckhouse	Chairman of the Board
Louis Scafuri	Chief Executive Officer
Fabian Tenenbaum	Chief Financial Officer
Karen Sarid	President & GM, Syneron Israel
Boris Vaynberg	Vice President, R&D

Contact Info

Fabian Tenenbaum, CFO	The Ruth Group
+ 972 73 244 2283	Nick Laudico / Zack Kubow
fabiant@syneron.com	646-536-7030 / 7020
	nlaudico@theruthgroup.com /
	zkubow@theruthgroup.com

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

